Cite

HARVARD Citation

    Home, P. et al. (2023). Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics. Diabetes, obesity & metabolism. 25 (3), pp. 656-663. [Online]. 
  
Back to record